US approves first new Alzheimer’s drug in 20 years

In March 2019, late-stage worldwide trials of aducanumab, involving about 3,000 sufferers, have been halted when evaluation confirmed it was no higher, given as a month-to-month infusion, at slowing the deterioration of reminiscence and pondering issues than a dummy drug.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *